PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer

Paz-Ares, Luis G., de Marinis, Filippo, Dediu, Mircea, Thomas, Michael, Pujol, Jean-Louis, Bidoli, Paolo, Molinier, Olivier, Sahoo, Tarini Prasad, Laack, Eckart, Reck, Martin, Corral, Jesús, Melemed, Symantha, John, William, Chouaki, Nadia, Zimmermann, Annamaria H., Visseren-Grul, Carla, Gridelli, Cesare·2013·Journal of Clinical Oncology

DOI 10.1200/jco.2012.47.1102

Cited by (622)

Items 101–200 of 622

Addressing the unmet need in lung cancer: The potential of immuno-oncology
Giorgio V. Scagliotti, Paolo Bironzo, Johan Vansteenkiste · 2015 · Cancer Treatment Reviews
A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC
Juliet A. Carmichael, Daisy Wing-san Mak, Mary O’Brien · 2018 · Cancers
Treatment Decisions for Advanced Non-Squamous Non-Small Cell Lung Cancer: Patient and Physician Perspectives on Maintenance Therapy
Suzanne McMullen, Lisa M. Hess, Edward S. Kim, Benjamin Philip Levy, Mohamed Mohamed, David Michael Waterhouse, Antoinette J. Wozniak, Sarah M. Goring, Kerstin Müller, Catherine Elizabeth Muehlenbein et al. · 2018 · Patient
Cumulative pemetrexed dose increases the risk of nephrotoxicity
Nikki de Rouw, René J. Boosman, Heidi van de Bruinhorst, Bonne Biesma, Michel M. van den Heuvel, David Marinus Burger, Luuk B. Hilbrands, Rob ter Heine, Hieronymus J. Derijks · 2020 · Lung Cancer
Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: COMPASS (WJOG5610L)
Takashi Seto, Koichi Azuma, Takeharu Yamanaka, Shunichi Sugawara, Hiroshige Yoshioka, Kazushige Wakuda, Shinji Atagi, Yasuo Iwamoto, Hidetoshi Hayashi, Isamu Okamoto et al. · 2019 · Journal of Clinical Oncology
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC
Caicun Zhou, Ziping Wang, Meili Sun, Lejie Cao, Zhiyong Ma, Rong Wu, Yan Yu, Wenxiu Yao, Si Sun, Jianhua Chen et al. · 2023 · Nature Cancer
Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
Jean-Louis Pujol, Luis G Paz-Ares, Filippo de Marinis, Mircea Dediu, Michael Thomas, Paolo Bidoli, Jesus Corral, Belén San Antonio, Nadia Chouaki, William J. John et al. · 2014 · Clinical Lung Cancer
Lung cancer surgery in oligometastatic patients: outcome and survival
Monica Casiraghi, Luca Bertolaccini, Giulia Sedda, Francesco Petrella, Domenico Galetta, Juliana Guarize, Patrick Maisonneuve, Filippo de Marinis, Lorenzo Spaggiari · 2020 · European Journal of Cardio-Thoracic Surgery
CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer
Tania Crombet, Pedro C. Rodríguez, Elia Nenínger Vinageras, Beatriz García Verdecia, Agustín Lage Dávila · 2015 · Expert Review of Vaccines
p53 mediated transcriptional regulation of long non-coding RNA by 1-hydroxy-1-norresistomycin triggers intrinsic apoptosis in adenocarcinoma lung cancer
Vaikundamoorthy Ramalingam, Varunkumar Krishnamoorthy, Vilwanathan Ravikumar, Rajendran Rajaram · 2018 · Chemico-Biological Interactions
Maintenance Chemotherapy With Chinese Herb Medicine Formulas vs. With Placebo in Patients With Advanced Non-small Cell Lung Cancer After First-Line Chemotherapy: A Multicenter, Randomized, Double-Blind Trial
Qin Wang, Lijing Jiao, Shengfei Wang, Peiqi Chen, Ling Bi, Di Zhou, Jialin Yao, Jiaqi Li, Zhiwei Chen, Yingjie Jia et al. · 2018 · Frontiers in Pharmacology
The emerging treatment landscape of advanced non-small cell lung cancer
Panagiota Economopoulou, Giannis Mountzios · 2018 · Annals of Translational Medicine
2020 Innovation-Based Optimism for Lung Cancer Outcomes
Erin Lynn Schenk, Tejas Patil, Jose M. Pacheco, Paul A. Bunn · 2020 · The Oncologist
Oral Chinese Herbal Medicine as Maintenance Treatment after Chemotherapy for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
Q. Wang, Q. Wang, Shuang Wang, Lijing Jiao, R.X. Zhang, Yucheng Zhong, J. Zhang, Luwei Xu · 2017 · Current Oncology
Improvement in Lung Cancer Outcomes With Targeted Therapies: An Update for Family Physicians
Christian Diego Rolfo, Francesco Passiglia, Marcin Ostrowski, Lucia Calisto Farracho, T. Ondoichova, Ana Dolcan, Marta Castiglia, Roy Remmen, Konstantinos Papadimitriou, Patrick Pauwels · 2015 · The Journal of the American Board of Family Medicine
The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non–Small Cell Lung Cancer
Noura J. Choudhury, Jessica A. Lavery, Samantha Brown, Ino de Bruijn, Justin Jee, Thinh Ngoc Tran, Hira A. Rizvi, Kathryn Cecilia Arbour, Karissa A. Whiting, Ronglai Shen et al. · 2023 · Clinical Cancer Research
International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease
Chengzhi Zhou, Yinyin Qin, Wei Ming Zhao, Zhenyu Liang, Min Li, Dan Liu, Li Bai, Yahong Chen, Yan Chen, Yuan Shan Cheng et al. · 2023 · Translational Lung Cancer Research
Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers.
Jody C. Chuang, Joel W. Neal · 2015 · PubMed
Personalized Therapy of Non-small Cell Lung Cancer (NSCLC)
Shirish M. Gadgeel · 2015 · Advances in experimental medicine and biology
Assessment of the External Validity of the National Comprehensive Cancer Network and European Society for Medical Oncology Guidelines for Non–Small-Cell Lung Cancer in a Population of Patients Aged 80 Years and Older
Nicolò Matteo Luca Battisti, Marina Sehovic, Martine Extermann · 2017 · Clinical Lung Cancer
Lung cancer requires multidisciplinary treatment to improve patient survival: A case report
Aldo Pezzuto, Fabrizio Terzo, Maria Laura Graziani, Alberto Rícci, Pierdonato Bruno, Salvatore Mariotta · 2017 · Oncology Letters
Overall survival in non-small cell lung cancer-what is clinically meaningful?
Klaus Fenchel, Ludger Sellmann, Wolfram C. M. Dempke · 2016 · Europe PMC (PubMed Central)
BRAF inhibitors in metastatic non-small cell lung cancer
Geòrgia Anguera, Margarita Majem · 2018 · Journal of Thoracic Disease
The current state of oligometastatic and oligoprogressive non-small cell lung cancer
Vasu Tumati, Puneeth Iyengar · 2018 · Journal of Thoracic Disease
[Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2020 Version)].
Caicun Zhou, Jie Wang, Baocheng Wang, Ying Cheng, Zhehai Wang, Baohui Han, You Lü, Gang Wu, Li Zhang, Yong Song et al. · 2021 · PubMed Central
Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer
Tudor–Eliade Ciuleanu, Samreen I. Ahmed, Joo-Hang Kim, Jörg Michael Mezger, Keunchil Park, Michael Thomas, Jihong Chen, Srinivasu Poondru, Jan M VanTornout, Debbie Whitcomb et al. · 2017 · British Journal of Cancer
Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer
Barbara L. Melosky · 2014 · Frontiers in Oncology
Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin
Jaewon Hyung, Bum Jun Kim, Changhoon Yoo, Kyo-Pyo Kim, Jae Ho Jeong, Heung-Moon Chang, Baek‐Yeol Ryoo · 2018 · Cancer Research and Treatment
PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors
Tarek M. Meniawy, Richard Lake, Alison M. McDonnell, Michael Millward, Anna K. Nowak · 2015 · Lung Cancer
Novel drug-resistance mechanisms of pemetrexed-treated non-small cell lung cancer
Ryosuke Tanino, Yukari Tsubata, Nanae Harashima, Mamoru Harada, Takeshi Isobe · 2018 · Oncotarget
Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells
Tamio Okimoto, Hitoshi Kotani, Yuichi Iida, Akira Koyanagi, Ryosuke Tanino, Yukari Tsubata, Takeshi Isobe, Mamoru Harada · 2020 · Cancer Science
MicroRNA 25 , microRNA 145 , and microRNA 210 as biomarkers for predicting the efficacy of maintenance treatment with pemetrexed in lung adenocarcinoma patients who are negative for epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations
Shengbin Shi, Meng Wang, Jing Tian, Rui Li, Chunxiao Chang, Jie-Lin Qi · 2015 · Translational research
Urine circulating-tumor DNA (ctDNA) detection of acquired EGFR T790M mutation in non-small-cell lung cancer: An outcomes and total cost-of-care analysis
Jacob M. Sands, Qianyi Li, John C Hornberger · 2017 · Lung Cancer
Treatment of Advanced Non-small-Cell Lung Cancer with Qi-Nourishing Essence-Replenishing Chinese Herbal Medicine Combined with Chemotherapy
Yabin Gong, XU Zhen-ye, Jin Chang-juan, Haibin Deng, Zhongqi Wang, Weidong Zhou, Ming Zhang, Xiaozhen Zhao, Lifang Wang · 2018 · Biological Procedures Online
Principles of Dose, Schedule, and Combination Therapy
William N. Hait, Joseph P. Eder · 2019 · Wiley eBooks
Crizotinib-Induced Abnormal Signal Processing in the Retina
Toshiyuki Ishii, Shunichiro Iwasawa, Ryota Kurimoto, Akemi Maeda, Yuichi Takiguchi, Makoto Kaneda · 2015 · PLoS ONE
The End of Nihilism: Systemic Therapy of Advanced Non–Small Cell Lung Cancer
Vinicius Ernani, Conor Ernst Steuer, Mohammad Jahanzeb · 2016 · Annual Review of Medicine
Quality of Life Analyses from the Randomized, Open-Label, Phase III PointBreak Study of Pemetrexed-Carboplatin-Bevacizumab followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer
David Robert Spigel, Jyoti D. Patel, Craig H. Reynolds, Edward B. Garon, Robert C. Hermann, Ramaswamy Govindan, Mark R. Olsen, Katherine B. Winfree, Jian Chen, Jingyi Liu et al. · 2015 · Journal of Thoracic Oncology
CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy
Kazuki Sone, Tetsuya Oguri, Makoto Nakao, Yusuke Kagawa, RYOTA KUROWAKA, Hiromi Furuta, Satoshi Fukuda, Takehiro Uemura, OSAMU TAKAKUWA, Yoshihiro Kanemitsu et al. · 2017 · Anticancer Research
Sumario ejecutivo de las recomendaciones SEPAR de diagnóstico y tratamiento del cáncer de pulmón de células no pequeñas
Felipe Villar Álvarez, Ignacio Muguruza Trueba, José Belda Sanchis, Laureano Molins López‐Rodó, Pedro Miguel Rodríguez Suárez, Julio Sánchez de Cos Escuín, Esther Barreiro, María Henar Borrego Pintado, Carlos Disdier Vicente, Javier Flandes Aldeyturriaga et al. · 2016 · Archivos de Bronconeumología
Interconversion of two commonly used performance tools: An analysis of 5844 paired assessments in 1501 lung cancer patients
Kuruswamy Thurai Prasad, Harpreet Kaur, Valliappan Muthu, Ashutosh N. Aggarwal, Digambar Behera, Navneet Singh · 2018 · World Journal of Clinical Oncology
Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review
Nagla Abdel Karim, Karen L. Kelly · 2019 · The Oncologist
Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis
Jiaqi Liang, Ming Li, Qihai Sui, Zhengyang Hu, Yunyi Bian, Yiwei Huang, Cheng Zhan, Wei Jiang, Qun Wang, Lijie Tan · 2020 · Translational Lung Cancer Research
PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis
Margarita Majem, Manuel Cobo, Dolores Isla, Diego Márquez-Medina, Delvys Rodríguez‐Abreu, Joaquín Casal‐Rubio, Teresa Morán, Reyes Bernabé, Diego Pérez-Parente, Pedro Ruiz Gracia et al. · 2021 · Journal of Clinical Medicine
Association of thyroid transcription factor‐1 with the efficacy of immune‐checkpoint inhibitors in patients with advanced lung adenocarcinoma
Kenji Nakahama, Hiroyasu Kaneda, Masahiko Osawa, Motohiro Izumi, Naoki Yoshimoto, Akira K. Sugimoto, Hiroaki Nagamine, Koichi Ogawa, Yoshiya Matsumoto, Kenji Sawa et al. · 2022 · Thoracic Cancer
State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer
Alessandro Inno, Vincenzo Di Noia, Ettore D’Argento, Alessandra Modena, Stefania Gori · 2016 · Translational Lung Cancer Research
Metformin synergistic pemetrexed suppresses non‐small‐cell lung cancer cell proliferation and invasion in vitro
Yan Zhang, Xiuli Feng, Tao Li, Erpan Yi, Yu Li · 2017 · Cancer Medicine
Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour
Jianrong Zhang, Yiyin Zhang, Shiyan Tang, Long Jiang, Qihua He, Lindsey Tristine Hamblin, Jiaxi He, Jieyu Wu, Jieyu Wu, Yaoqi Chen et al. · 2018 · BMJ Open
A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer
Nabil Mubarak, Rabab Mohamed Gaafar, Samir Shehata, Tarek Hashem, Dani Abigeres, Hamdy A. Azim, Gamal A. El-Husseiny, Hamed Alhusaini, Zhixin Liu · 2012 · BMC Cancer
Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group
Jordi Remón, Ernest Nadal, Manuel Dómine, José Carlos Ruffinelli, Yolanda García García, Juan Carlos Pardo, R. López, Ángel Cilleruelo Ramos, Rosario García‐Campelo, P. Martín et al. · 2020 · Lung Cancer
Factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer patients
Yahua Wu, Haishan Wu, Mingqiang Lin, Tianxiu Liu, Jiancheng Li · 2021 · Translational Oncology
Pemetrexed induced acute kidney injury in patients with non-small cell lung cancer: reversible and chronic renal damage
Giuseppe Rombolà, Franco Vaira, Matteo Trezzi, Nadia Chiappini, Valeria Falqui, Francesco Londrino · 2014 · Journal of Nephrology
The evolving role of pemetrexed disodium for the treatment of non-small cell lung cancer
Giovanni Rossi, Angela Alama, Carlo Genova, Erika Rijavec, Marco Tagliamento, Federica Biello, Simona Coco, Maria Giovanna Dal Bello, Simona Boccardo, Francesco Grossi · 2018 · Expert Opinion on Pharmacotherapy
Global research landscape and trends of lung cancer immunotherapy: A bibliometric analysis
Yanhao Liu, Cheng Xu, Xiaona Han, Xi Cheng, Shu Jiang, Yaru Lin, Zhen Zhang, Linlin Lu, Baozhen Qu, Yuxian Chen et al. · 2022 · Frontiers in Immunology
Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review)
Ralph Zinner, Carla Visseren‐Grul, David Robert Spigel, Coleman K. Obasaju · 2015 · International Journal of Oncology
Treatment algorithm in 2014 for advanced non-small cell lung cancer: Therapy selection by tumour histology and molecular biology
Christian Manegold · 2014 · Advances in Medical Sciences
EGFR–TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation
Dong‐Hoe Koo, Kyu‐pyo Kim, Chang‐Min Choi, Dae-Ho Lee, Jae Cheol Lee, Jung‐Shin Lee, Se Jin Jang, Sang‐We Kim · 2014 · Cancer Chemotherapy and Pharmacology
Preparation and Evaluation of Stearylamine-Bearing Pemetrexed Disodium-Loaded Cationic Liposomes In Vitro and In Vivo
Kongfang He, Jingjing Liu, Yan Gao, Yanyun Hao, Xuehua Yang, Guihua Huang · 2020 · AAPS PharmSciTech
The impact of personalized medicine on survival: Comparisons of results in metastatic breast, colorectal and non-small-cell lung cancers
Antônio Rossi, Valter Torri, Marina Chiara Garassino, Luca Porcu, Domenico Galetta · 2013 · Cancer Treatment Reviews
Factors associated with the prognosis and long-term survival of patients with metastatic lung adenocarcinoma: a retrospective analysis
Chen‐Yang Huang, Bo-Huan Chen, Wen‐Chi Chou, Cheng‐Ta Yang, John Wen‐Cheng Chang · 2018 · Journal of Thoracic Disease
Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study
Seiji Niho, Tatsuya Yoshida, Tetsuo Akimoto, Kentaro Sakamaki, Akira Ono, Takashi Seto, Makoto Nishio, Noboru Yamamoto, Toyoaki Hida, Hiroaki Okamoto et al. · 2020 · Lung Cancer
Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)–Positive Non–Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors
Abhay Singh, Hongbin Chen · 2020 · Cancer Management and Research
Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non–Small-Cell Lung Cancer
Ying Liang, Heather A. Wakelee, Joel W. Neal · 2014 · Clinical Lung Cancer
Non–Small Cell Lung Cancer Metastatic Without Oncogenic Alterations
Nikolaj Frost, Martin Reck · 2024 · American Society of Clinical Oncology Educational Book
Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer-the Holy Grail in cancer treatment?
Ludger Sellmann, Klaus Fenchel, Wolfram C. M. Dempke · 2015 · Europe PMC (PubMed Central)
The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review
Swati Kulkarni, Emily T. Vella, Nadia Coakley, Susanna Yee-Shan Cheng, Richard William Gregg, Yee Ung, Peter M. Ellis · 2016 · Journal of Thoracic Oncology
Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): Do gender and sex matter?
Stefano Frega, Alessandro Dal Maso, Alessandra Ferro, Laura Bonanno, PierFranco Conte, Giulia Pasello · 2019 · Critical Reviews in Oncology/Hematology
Blood mRNA expression of REV3L and TYMS as potential predictive biomarkers from platinum-based chemotherapy plus pemetrexed in non-small cell lung cancer patients
María Teresa Agulló-Ortuño, Inmaculada García‐Ruíz, C. Vanesa Díaz-García, Ana B. Enguita, Virginia Pardo, Elena Prieto‐García, Santiago Ponce, L. Iglesias, Jon Zugazagoitia, Jose Antonio Lopez-Martin et al. · 2019 · Cancer Chemotherapy and Pharmacology
Challenges and Novel Opportunities of Radiation Therapy for Brain Metastases in Non-Small Cell Lung Cancer
Paola Anna Jablonska, Joaquim Bosch‐Barrera, Diego Serrano, Manuel Valiente, Alfonso Calvo, Javier Aristu · 2021 · Cancers
Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis
Lei Sheng, Jing Gao, Qian Xu, Xue Zhang, Miao Huang, Xin Dai, Song Li, Lian Liu · 2021 · Therapeutic Advances in Medical Oncology
Feasibility of home delivery of pemetrexed in patients with advanced non-squamous non-small cell lung cancer
Rohit Lal, Gunnar Hillerdal, Riyaz N.H. Shah, Barbara Crosse, Joyce Thompson, Marianne C. Nicolson, Anders Vikström, Vanessa Alice Potter, Carla Visseren‐Grul, M. Lorenzo et al. · 2015 · Lung Cancer
Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials
Giorgio V. Scagliotti, Cesare Gridelli, Filippo de Marinis, Michael Thomas, Mircea Dediu, Jean-Louis Pujol, Ch. Manegold, Belén San Antonio, Patrick M. Peterson, William J. John et al. · 2014 · Lung Cancer
Nintedanib in NSCLC: evidence to date and place in therapy
Giuseppe Bronte, Francesco Passiglia, Antonio Galvano, Nadia Barraco, Angela Listì, Marta Castiglia, Sérgio Rizzo, Eugenio Fiorentino, Viviana Bazan, Antonio Dello Russo · 2016 · Therapeutic Advances in Medical Oncology
Meta‐analysis of first‐line therapies with maintenance regimens for advanced non‐small‐cell lung cancer (NSCLC) in molecularly and clinically selected populations
Pui San Tan, Marcel Bilger, Gilberto De Lima Lopes Jr., Sanchalika Acharyya, Benjamin Adam Haaland · 2017 · Cancer Medicine
Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non–Small-Cell Lung Cancer
Tudor–Eliade Ciuleanu, Mark A. Socinski, Coleman K. Obasaju, Alexander Valerievich Luft, Aleksandra Szczęsna, W Szafrański, Rodryg Ramlau, Beatrix Bálint, Olivier Molinier, Henrik Depenbrock et al. · 2017 · Clinical Lung Cancer
Comparative efficacy of first-line ceritinib and crizotinib in advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer: an adjusted indirect comparison with external controls
Junlong Li, Stefanie Knoll, Iryna Bocharova, Wenxi Tang, James Signorovitch · 2018 · Current Medical Research and Opinion
Safety profiles of first-line therapies for metastatic non-squamous non-small-cell lung cancer
Tania Losanno, Cesare Gridelli · 2016 · Expert Opinion on Drug Safety
A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer
James Chih‐Hsin Yang, Tony S.K. Mok, Baohui Han, Mauro Orlando, Tarun Puri, Keunchil Park · 2017 · Clinical Lung Cancer
First-Line Crizotinib in ALK-Positive Lung Cancer
Ali Alkan, Elif Berna Köksoy, Güngör Utkan · 2015 · New England Journal of Medicine
The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials
Krista L. Noonan, Cheryl Ho, Janessa J. Laskin, Nevin Murray · 2015 · Journal of Thoracic Oncology
Anti-angiogenesis in Personalized Therapy of Lung Cancer
Peter M. Ellis · 2015 · Advances in experimental medicine and biology
Pharmacological and clinical properties of lorlatinib in the treatment of ALK-rearranged advanced non-small cell lung cancer
Haidar El Darsa, Omar Mohammed Abdel-Rahman, Randeep S. Sangha · 2020 · Expert Opinion on Pharmacotherapy
Predictive Radiomic Models for the Chemotherapy Response in Non-Small-Cell Lung Cancer based on Computerized-Tomography Images
Runsheng Chang, Shouliang Qi, Yong Yue, Xiaoye Zhang, Jiangdian Song, Wei Qian · 2021 · Frontiers in Oncology
Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy
Ondřej Fiala, Miloš Pešek, Jana Skřičková, Vı́tězslav Kolek, František Salajka, Marcela Tomíšková, Monika Šatánková, Juraj Kultan, Jana Kulísková, Martin Svatoň et al. · 2017 · Tumor Biology
A Neuro-oncologist’s Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer
Tresa Michelle McGranahan, Seema Nagpal · 2017 · Current Treatment Options in Oncology
Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials
Jasmine C. Huynh, Kanishka GopikaBimal Patel, Jun Gong, May Thet Cho, Midhun Malla, Aparna R. Parikh, Samuel Jacob Klempner · 2021 · Current Treatment Options in Oncology
Maintaining clarity: Review of maintenance therapy in non-small cell lung cancer
Kristen R. Dearing · 2014 · World Journal of Clinical Oncology
Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): in which patients, with which drugs?
Valentina Polo, Benjamin Besse · 2013 · Annals of Oncology
Randomized Phase III Study of Docetaxel Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-line Treatment of Nonsquamous Non–Small-cell Lung Cancer: A TRAIL Trial
Cheol‐Kyu Park, In‐Jae Oh, Kyu Sik Kim, Yoo-Duk Choi, Tae Won Jang, Youn-Seup Kim, Kwan-Ho Lee, Kyeong Cheol Shin, Chi Young Jung, Sei Hoon Yang et al. · 2017 · Clinical Lung Cancer
Efficacy of pemetrexed-based regimens in advanced non–small cell lung cancer patients with activating epidermal growth factor receptor mutations after tyrosine kinase inhibitor failure: a systematic review
Han Bao Hui, Lu Lu Yang, Xin Wang, Luan Di Yao · 2018 · OncoTargets and Therapy
Percutaneous CT-guided microwave ablation as maintenance after first-line treatment for patients with advanced NSCLC
Junqing Han, Xiang Ni, Xin Ye, Zhigang Wei · 2015 · OncoTargets and Therapy
Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network meta-analysis
Mingye Zhao, Taihang Shao, Yinan Ren, Caicun Zhou, Wenxi Tang · 2022 · Frontiers in Pharmacology
Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting
Marion Sassier, Audrey Emmanuelle Dugué, Bénédicte Clarisse, Paul Lesueur, Virginie Avrillon, Acya Bizieux‐Thaminy, J.B. Auliac, Laure Kaluzinski, J. Tillon, G. Robinet et al. · 2015 · Lung Cancer
Maintenance treatment after induction therapy in non-small cell lung cancer: latest evidence and clinical implications
Ryan D. Gentzler, Jyoti D. Patel · 2013 · Therapeutic Advances in Medical Oncology
Executive Summary of the SEPAR Recommendations for the Diagnosis and Treatment of Non-small Cell Lung Cancer
Felipe Villar Álvarez, Ignacio Muguruza Trueba, José Belda Sanchis, Laureano Molins López‐Rodó, Pedro Miguel Rodríguez Suárez, Julio Sánchez de Cos Escuín, Esther Barreiro, María Henar Borrego Pintado, Carlos Disdier Vicente, Javier Flandes Aldeyturriaga et al. · 2016 · Archivos de Bronconeumología
Comparison of next‐generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations
Shuji Murakami, Tomoyuki Yokose, Kanako Shinada, Testuya Isaka, Kengo Katakura, Ryouta Ushio, Tetsuro Kondo, Terufumi Kato, Hiroyuki Ito, Haruhiro Saito · 2022 · Thoracic Cancer
Long term responders to palliative chemotherapy for advanced biliary tract cancer
Mark K. Doherty, Mairead Geraldine McNamara, Priya Aneja, Emma McInerney, Stephanie Moignard, Anne M. Horgan, Haiyan Jiang, Tony Panzarella, Raymond Jang, Neesha C. Dhani et al. · 2017 · Journal of Gastrointestinal Oncology
CACA guidelines for holistic integrative management of lung cancer
Jun Wang · 2024 · Holistic Integrative Oncology
Maintenance therapy in non-small cell lung cancer
Giovenzio Genestreti, Monica Di Battista, Giovanna Cavallo, Marco Bartolotti, Alba Ariela Brandes · 2015 · Expert Review of Anticancer Therapy
Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer
Ana Turkaj, Anna Maria Morelli, Tiziana Vavalà, Silvia Novello · 2018 · Frontiers in Oncology